Nine for 2019: Challenges impacting pharma

As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.

The close of 2018 saw the number of approvals at a five year high for both the FDA and the EMA. We’ve seen remarkable breakthroughs – in cancer, for rare diseases, and with next generation biotherapeutics such as gene therapies, and cell therapies.